A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

(2013) Pedro MM Mesquita et al.   Retrovirology

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

(2012) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexposure Prophylaxis for HIV Infection among African Women

(2012) Lut Van Damme et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel

(2011) Marla J. Keller et al.   PLoS One

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Coexistence of passive and carrier-mediated processes in drug transport

(2010) Kiyohiko Sugano et al.   NATURE REVIEWS DRUG DISCOVERY

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

(2009) Wendy P Bannister et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS